Columnar Cell Variant of Papillary Thyroid Carcinoma: A Clinicopathologic Analystis
European Journal of Clinical and Biomedical Sciences
Volume 5, Issue 1, February 2019, Pages: 16-20
Received: Oct. 14, 2018;
Accepted: Jan. 21, 2019;
Published: May 8, 2019
Views 718 Downloads 81
Zhang Gang, Department of Surgical Oncology, The First Central Hospital of Baoding, Baoding, China
Zhao Xing, Department of Pathology, Chengde Medical College Affiliated Hospital, Chengde, China
Sun Jirui, Department of Pathology, The First Central Hospital of Baoding, Baoding, China
Zhang Jinku, Department of Pathology, The First Central Hospital of Baoding, Baoding, China
Zhang Jinzhuo, Department of Digestive System, The First Central Hospital of Baoding, Baoding, China
Background: Papillary Thyroid Carcinoma (PTC) is the Most common thyroid malignancy disease, and it is more common in females. It happened in any age. Mean age at diagnosis is approximately 40 years old. There is history of neck irradiation in 5–10% patients. And non-neoplastic gland may show nuclear aberrations as a result. There is increased incidence in Hashimoto's thyroiditis, but not clear whether there is an increased incidence in Graves' disease. Columnar cell variant of papillary thyroid carcinoma is the rare subtype of PTC, which is reportedly about 0.17%. CCV-PTC was reported in 1986 by Evans for the first time. It is different from the typical papillary carcinoma, not only in morphology but also in biological behavior, and is more aggressive than typical papillary carcinoma. Objective: To study the clinical-pathological links and features of papillary thyroid carcinoma (Columnar cell variant) (CCV-PTC). Methods: 4 cases of CCV-PTC from Chengde medical college affiliated hospital were retrospectively analyzed, to observe its clinical features, histological, immunophenotype, and metastasis. And the literature of CCV-PTC were reviewed. Results: Out of the 4 patients, two male patients of 70 and 53 years old, two female patients of 64 and 68 years old. Microscopically, tumor cells arranged in multistage papillary structure, with pseudostratified columnar epithelium, same to gastrointestinal and lung metastatic carcinoma. IHC: Ki-67(5-15%), calcitonin(-), TG(+), ck19(-), TTF-1(+), CgA(-), SyN(-),ck(+/-). Conclusion: CCV-PTC is a special subtype of PTC with a more aggressive biological behavior, particularly among older people, Immunohistochemical method is helpful for the diagnosis.
Columnar Cell Variant of Papillary Thyroid Carcinoma: A Clinicopathologic Analystis, European Journal of Clinical and Biomedical Sciences.
Vol. 5, No. 1,
2019, pp. 16-20.
Bongiovanni M, Mermod M, Canberk S, et al.Columnar cell variant of papillary thyroid carcinoma:Cytomorphological characteristics of 11 cases with histological correlation and literature review. Cancer Cytopathol, 2017, 125 (6): 389-397.
Song E, Jeon MJ, Oh HS, et al. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma? Eur J Endocrinol. 2018, 179 (3): 135-142.
Ito Y, Miyauchi A, Kihara M, et al.Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Insititution Long-Term Follow-Up of 5879 Patients.World J Surg. 2018, 42 (3): 615-622.
Marie Hlaváčková.Columnar cell variant of papillary thyroid carcinoma. Endocrine Abstracts, 2017, 49: 1438.
Chen JH1, Faquin WC, Lloyd RV, et al. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma [J]. Mod Patho, 2011, 24 (5): 739-749
Evans HL. Columnar-cell carcinoma of the thyroid: a report of two cases of an aggressive variant of thyroid carcinoma [J]. Am J Clin Pathol, 1986, 85 (1): 77 - 80.
J Cho, JH Shin, SY Hahn, etal. Columnar Cell Variant of Papillary Thyroid Carcinoma: Ultrasonographic and Clinical Differentiation between the Indolent and Aggressive Types.
Korean Journal of Radiology, 2018, 19(5): 1000.  C Jiang, T Cheng, X Zheng, etal. Clinical behaviors of rare variants of papillary thyroid carcinona are associated with survival: a population-level analysis. Cancer Management and Research, 2018, 10: 465-472.
Rottuntikarn W, Wangsiricharoen S, Rangdaeng S. Cytomorphology and immunocytochemistry of columnar cell variant of papillary thyroid carcinoma [J]. Cytopathology, 2017, 28 (4): 338-341.
Enriquez M L, Baloch Z W, Montone K T, et al. CDX2 expression in columnar cell variant of papillary thyroid carcinoma [J]. American Journal of Clinical Pathology, 2012, 137 (5): 722.
Sujoy V, Pinto A, Nosś V. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression. Thyroid. 2013; 23: 714–71
Suh S, Kim Y H, Goh T S, et al. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas. [J]. Yonsei Medical Journal, 2018, 59 (6): 746.
Kim H I, Kim T H, Choe J H, et al. Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis [J]. British Journal of Surgery, 2018, 105 (3): 270.
Liu R, Bishop J, Zhu G, et al. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality. [J]. Jama Oncology, 2016, 3288.
Yin D, Han Y, Zhang Y, et al. Clinicopathologic and neck metastasis features of multifocal papillary thyroid cancer [J]. Chinese Journal of General Surgery, 2017 (5): 556-559.
Liao T, Wen D, Ma B, et al. Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway [J]. Oncotarget, 2017, 8 (7): 11719-11728.
Liang J, Cai W, Feng D, et al. Genetic landscape of papillary thyroid carcinoma in the Chinese population [J]. Journal of Pathology, 2017, 244 (2): 215-226.
Jayaram G. Cytology of columnar-cell variant of papillary thyroid carcinoma. [J]. Diagnostic Cytopathology, 2015, 22 (4): 227-229.
Nath M C, Erickson L A. Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid. [J]. Advances in Anatomic Pathology, 2018, 25 (3): 1.